Tue, Sep 16, 2014, 11:49 AM EDT - U.S. Markets close in 4 hrs 11 mins

Recent

% | $
Quotes you view appear here for quick access.

Dynavax Technologies Corporation Message Board

dghurt66 8 posts  |  Last Activity: Jul 29, 2014 11:31 PM Member since: May 7, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • When Hyde exits some shares from AutoZone, buy all you can...

    Sentiment: Strong Buy

  • Reply to

    Next Catalyst For GTXI Stock Price.

    by dmdlbt Jul 27, 2014 9:00 PM
    dghurt66 dghurt66 Jul 29, 2014 11:17 PM Flag

    When do we see the survival data on Enbosarm 3, and submission of existing data to EMA?

  • dghurt66 by dghurt66 Jul 23, 2014 12:52 PM Flag

    News coming.

    Sentiment: Strong Buy

  • Reply to

    Morning Star rates GTXI as UNDERVALUED

    by texastea666 Jul 10, 2014 11:07 AM
    dghurt66 dghurt66 Jul 23, 2014 12:42 PM Flag

    News coming this month.

    Sentiment: Strong Buy

  • dghurt66 by dghurt66 Jul 23, 2014 7:07 AM Flag

    Will be GTXI. Expecting FDA approval. on Ph II of Enbosarm 9mg by end of July. Preliminary results show 41% achieved Clinical benefit for breast cancer. Also submitting Ph III of Enbosarm 3 mg to EMA.
    Read below prelim results.
    GTx, Inc. announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm, a selective androgen receptor modulator, for the treatment of patients with androgen receptor positive and estrogen receptorpositive metastatic breast cancer who have previously responded to hormonal therapy. The clinical data is being presented today during the Breast Cancer-HER2/ER poster session at the 50th Annual Meeting of the American Society of Clinical Oncolog in Chicago. The Phase 2 open-label study is evaluating 22 postmenopausal women with ER positive metastatic breast cancer, who had previously responded to adjuvant hormonal therapy for three years or longer, and women diagnosed with metastatic disease, who had been treated with hormonal therapy for at least six months, prior to disease progression. Study participants were heavily pretreated. The mean time from initial breast cancer diagnosis is 11 years and the mean age of patients is 64 years. Of the 22 patients enrolled in the study, a total of 20 patients had one or more scheduled assessments for determination of clinical benefit. The primary endpoint was assessed in 17 AR+ patients with 6 patients demonstrating clinical benefit at six months, exceeding the pre-defined statistical threshold requiring that at least 3 of 14 patients with an AR+ metastatic lesion demonstrate clinical benefit. Additionally, results showed that, after a median duration on study of 81 days, 41 percent of all patients achieved clinical benefit as best response and also had increased prostate specific antigen, which appears to be an indicator of AR activity

  • Reply to

    Look to the right

    by arfmooocat Jul 7, 2014 2:40 PM
    dghurt66 dghurt66 Jul 7, 2014 8:16 PM Flag

    Time is running out. Load up

    Sentiment: Strong Buy

  • dghurt66 by dghurt66 Jul 4, 2014 7:49 PM Flag

    The guy they canned, that went from $300k to $48k / year sold some more shares. Three insiders bought.

    Sentiment: Strong Buy

  • Reply to

    News Coming GTX-027

    by ioakyri Jun 30, 2014 10:25 AM
    dghurt66 dghurt66 Jul 3, 2014 4:30 AM Flag

    Survival data due also

    Sentiment: Strong Buy

DVAX
1.325-0.055(-3.99%)11:46 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.